JAK Inhibition in PNPT1 ‐Related Mitochondrial Interferonopathy: A Case Report and Review of Mitochondrial–Immune Crosstalk
JIMD Reports · 2026-07 · 67 (4)
DOI: 10.1002/jmd2.70096 ↗Kurz gefasst
Fallbericht in der Zeitschrift JIMD Reports, online erschienen am 29.06.2026. Verfasst von Dan Ross Brooks und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ACMG Foundation for Genetic and Genomic Medicine.
Abstract (Originalsprache)
Biallelic pathogenic variants in PNPT1 cause combined oxidative phosphorylation deficiency 13 (COXPD13) (MIM #614932), linking mitochondrial dysfunction to type I interferon (IFN) activation through cytosolic leakage of mitochondrial double‐stranded RNA (mt‐dsRNA). This mechanism connects mitochondrial disease to interferonopathies such as Aicardi–Goutières syndrome (AGS). We describe a 7‐month‐old female infant with compound heterozygous PNPT1 variants presenting with severe hypotonia, feeding difficulties necessitating gastrostomy, dystonia, and elevated serum lactate. Brain magnetic resonance imaging (MRI) demonstrated marked cerebellar, brainstem, and basal ganglia atrophy, with a lactate peak on MR spectroscopy (consistent with an inverted doublet). Serum immune profiling revealed a mild but elevated type I IFN signature. Given the mechanistic overlap with AGS, off‐label tofacitinib, a Janus kinase (JAK) inhibitor that blocks IFN‐driven JAK/STAT signaling, was initiated following pediatric interferonopathy dosing protocols. Tofacitinib was associated with normalization of serum type I IFN biomarkers, reduction in lactate and transaminases, improvement in dystonic movements, ventilatory stability, and improved growth/nutrition without treatment‐limiting adverse events. To our knowledge, this represents the first reported use of JAK inhibition in COXPD13. The observed clinical and biochemical stabilization supports defining COXPD13 as a “mitochondrial interferonopathy” and suggests that IFN‐signature screening may identify mitochondrial disease patients who could benefit from targeted immunomodulation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA.
- Texas Children's Hospital Houston Texas USA.
- Division of Neurology, Department of Pediatrics Baylor College of Medicine Houston Texas USA.
- Division of Neurology Texas Children's Hospital Houston Texas USA.
- Division of Allergy & Immunology, Department of Pediatrics Baylor College of Medicine Houston Texas USA.
- Division of Allergy & Immunology Texas Children's Hospital Houston Texas USA.
ORCID-Profile: Taylor Martin Kerrins, Chaya Nautiyal Murali, Fernando Scaglia
Förderung
- ACMG Foundation for Genetic and Genomic Medicine
Zitieren
APA
Brooks, D. R., Koh, H. Y., Kerrins, T. M., Lang, S., Bland, E., Yang, R., Nicholas, S. K., Sikkink, S. J., Kralik, S., Eng, C., Murali, C. N., Lalani, S., Magoulas, P. L., Emrick, L., Fisher, K. S., & Scaglia, F. (2026). JAK Inhibition in PNPT1 ‐Related Mitochondrial Interferonopathy: A Case Report and Review of Mitochondrial–Immune Crosstalk. JIMD Reports, 67(4). https://doi.org/10.1002/jmd2.70096
Vancouver
Brooks DR, Koh HY, Kerrins TM, Lang S, Bland E, Yang R, et al. JAK Inhibition in PNPT1 ‐Related Mitochondrial Interferonopathy: A Case Report and Review of Mitochondrial–Immune Crosstalk. JIMD Reports. 2026;67(4). doi:10.1002/jmd2.70096
BibTeX
@article{Brooks2026,
author = {Brooks, Dan Ross and Koh, Hyun Yong and Kerrins, Taylor Martin and Lang, Steven and Bland, Emily and Yang, Rui and Nicholas, Sarah Kogan and Sikkink, Stephanie Jean and Kralik, Stephen and Eng, Christine and Murali, Chaya Nautiyal and Lalani, Seema and Magoulas, Pilar Lenglet and Emrick, Lisa and Fisher, Kristen Sydney and Scaglia, Fernando},
title = {JAK Inhibition in PNPT1 ‐Related Mitochondrial Interferonopathy: A Case Report and Review of Mitochondrial–Immune Crosstalk},
journal = {JIMD Reports},
year = {2026},
volume = {67},
number = {4},
doi = {10.1002/jmd2.70096}
}
EUVIMED